Bajaj Healthcare

Why is Bajaj Healthcare Ltd falling/rising?

As of 08-Aug, Bajaj Healthcare Ltd's stock price is currently 329.30, reflecting a decline of -20.70% year-to-date and underperforming against the Sensex. The stock has been falling for four consecutive days, with decreased investor participation and a bearish trend indicated by its moving averages.

As of 08-Aug, Bajaj Healthcare Ltd's stock price is falling, currently at 329.30, reflecting a change of -0.2 (-0.06%). The stock has been underperforming significantly compared to the benchmark Sensex, with a decline of -2.18% over the past week while the Sensex gained +0.52%. Over the last month, the stock has also decreased by -0.62%, contrasting with the Sensex's +0.41% increase. Year-to-date, Bajaj Healthcare Ltd has seen a substantial drop of -20.70%, compared to the Sensex's decline of only -7.89%. <BR><BR>Additionally, the stock has been on a consecutive fall for the last four days, resulting in a total decline of -3.89% during this period. The stock's performance today has underperformed its sector by -0.88%. Furthermore, there is a notable decrease in investor participation, with delivery volume dropping by -23.1% against the five-day average. Although the stock is trading higher than its 50-day and 100-day moving averages, it is lower than its 5-day, 20-day, and 200-day moving averages, indicating a bearish trend. Overall, these factors contribute to the ongoing decline in Bajaj Healthcare Ltd's stock price.

Which are the latest news on Bajaj Healthcare?

Are Bajaj Healthcare Ltd latest results good or bad?

Bajaj Healthcare Ltd's latest results show a significant recovery in net profit and sales growth, indicating improved operational performance. However, concerns about long-term sales decline and profitability sustainability suggest caution in evaluating the company's overall health.

Bajaj Healthcare Ltd's latest results show a mixed picture. On one hand, the company reported a significant recovery in net profit, achieving ₹13.89 crores, which is a remarkable 171.54% increase quarter-on-quarter and a 14.13% increase year-on-year. This recovery follows a challenging previous quarter where the company posted a loss.<BR><BR>Net sales also grew, reaching ₹165.63 crores, marking an 8.21% increase from the previous quarter and an 11.28% increase year-on-year, which is the highest quarterly revenue in recent history. Additionally, operating margins improved to 17.36%, up from 14.82% in the prior quarter, indicating better cost management.<BR><BR>However, despite these positive developments, there are underlying concerns. The company has faced a long-term decline in sales and profitability, with a five-year annual sales decline of 1.44% and EBIT contraction of 8.46%. The current profitability, while improved, still raises questions about sustainability, especially given the volatility in quarterly earnings.<BR><BR>In summary, while the latest results indicate a recovery and improved operational metrics, the persistent structural challenges and historical performance issues suggest that caution is warranted when evaluating the overall health of Bajaj Healthcare Ltd.

Should I buy, sell or hold Bajaj Healthcare Ltd?

What does Bajaj Healthcare do?

Bajaj Healthcare Ltd is a micro-cap bulk drug manufacturer in the Pharmaceuticals & Biotechnology industry, established in 1993 and publicly listed since 2005. As of March 2026, it reported net sales of ₹153 Cr and a net loss of ₹23 Cr, with a market cap of ₹984 Cr.

Overview: <BR>Bajaj Healthcare Ltd is a bulk drug manufacturer operating in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History: <BR>Bajaj Healthcare Ltd was established in 1993 and became a public company in 2005. It listed its shares on the Indian stock exchanges in 2016. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 153 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -23 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 984 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 18.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.32% <BR>Debt-Equity: 0.46 <BR>Return on Equity: 11.13% <BR>Price to Book: 2.02<BR><BR>Contact Details: <BR>Address: 602-606 Bhoomi Velocity Infote, Road No 23 Wagle Indl Estate Thane Maharashtra : 400604 <BR>Tel: 91-22-66177400/401 <BR>Email: investors@bajajhealth.com <BR>Website: http://www.bajajhealth.com

How big is Bajaj Healthcare?

As of 10th June, Bajaj Healthcare Ltd has a market capitalization of 984.00 Cr, with recent net sales of 611.03 Cr and a net profit of 15.76 Cr. The company reported shareholder's funds of 466.16 Cr and total assets of 814.15 Cr for the latest annual period ending March 2025.

As of 10th June, Bajaj Healthcare Ltd has a market capitalization of 984.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Bajaj Healthcare reported Net Sales of 611.03 Cr and a Net Profit of 15.76 Cr.<BR><BR>For the latest annual period ending March 2025, the company had Shareholder's Funds of 466.16 Cr and Total Assets amounting to 814.15 Cr.

Who are in the management team of Bajaj Healthcare?

The management team of Bajaj Healthcare includes Sanjankumar R Bajaj (Chairman & Managing Director), Anil C Jain (Joint Managing Director), and several other directors, including independent and whole-time directors, overseeing the company's governance and strategic direction.

The management team of Bajaj Healthcare includes the following key individuals:<BR><BR>1. **Sanjankumar R Bajaj** - Chairman & Managing Director<BR>2. **Anil C Jain** - Joint Managing Director<BR>3. **Namrata S Bajaj** - Whole-time Director<BR>4. **Dhananjay S Halte** - Whole-time Director<BR>5. **Rupesh H Nikam** - Whole Time Director & CFO<BR>6. **Ram B Banarase** - Independent Director<BR>7. **Hemant R Karnik** - Independent Director<BR>8. **Aakashkumar Kesari** - Company Secretary<BR>9. **Avinash Dalal** - Independent Director<BR>10. **Loukik D Tipnis** - Independent Director<BR>11. **Luke Benedict Fernandez** - Independent Director<BR>12. **Kejal Shah** - Independent Director<BR>13. **Pakshal Jain** - Director<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

Who are the peers of the Bajaj Healthcare?

Bajaj Healthcare's peers include Jagsonpal Pharma, Lincoln Pharma, Fredun Pharma, and others. While Bajaj Healthcare shows below-average growth and a 1-year return of -44.41%, peers like Fredun Pharma exhibit excellent growth and a return of 211.49%.

Peers: The peers of Bajaj Healthcare are Jagsonpal Pharma, Lincoln Pharma., Fredun Pharma, Fermenta Biotec., Themis Medicare, Bharat Parenter., Wanbury, Kopran, Accent Microcell, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jagsonpal Pharma, Lincoln Pharma., and Accent Microcell, while Average management risk is found at Fredun Pharma, Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Bharat Parenter., Wanbury, Kopran, and Remus Pharma. Growth is Excellent at Fredun Pharma and Good at Wanbury and Accent Microcell, while Below Average growth is noted for Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Lincoln Pharma., Jagsonpal Pharma, Bharat Parenter., and Kopran. Capital Structure is Excellent at Jagsonpal Pharma, Lincoln Pharma., and Accent Microcell, while Below Average is found at Bajaj Healthcare, Fermenta Biotec., Themis Medicare, and Wanbury, and Average at Bharat Parenter. <BR><BR>Return Snapshot: Fredun Pharma has the highest 1-year return at 211.49%, while Bajaj Healthcare has the lowest at -44.41%. This indicates that Bajaj Healthcare's 1-year return is significantly worse than that of Fredun Pharma. Additionally, peers with a negative six-month return include Bajaj Healthcare, Themis Medicare, and Wanbury.

Is Bajaj Healthcare technically bullish or bearish?

As of December 1, 2025, Bajaj Healthcare's technical trend has shifted to a moderate bearish stance, indicated by bearish MACD, Bollinger Bands, and moving averages, despite a mildly bullish KST signal on the weekly chart.

As of 1 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Bajaj Healthcare is bearish with a moderate strength. Key indicators driving this stance include the bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and a bearish moving average on the daily chart. The KST shows a mildly bullish signal on the weekly but remains mildly bearish on the monthly, indicating some divergence. Overall, the lack of strong signals from the RSI and Dow Theory further supports the bearish outlook.

How has been the historical performance of Bajaj Healthcare?

Bajaj Healthcare's historical performance has shown significant fluctuations, with net sales peaking at 645.80 Cr in Mar'23 but declining to 542.60 Cr by Mar'25, alongside decreases in profit metrics and cash flow, despite an increase in total assets. Overall, the company has faced both growth and challenges in its financial performance.

Answer:<BR>The historical performance of Bajaj Healthcare shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Bajaj Healthcare's net sales have experienced variability, peaking at 645.80 Cr in Mar'23 before declining to 542.60 Cr in Mar'25. The total operating income followed a similar trend, with a high of 679.89 Cr in Mar'22 and a decrease to 542.60 Cr in Mar'25. Raw material costs rose from 291.33 Cr in Mar'19 to 307.11 Cr in Mar'25, while total expenditure, excluding depreciation, increased from 327.55 Cr in Mar'19 to 460.17 Cr in Mar'25. Operating profit (PBDIT) fluctuated, reaching a high of 143.23 Cr in Mar'21 but dropping to 101.83 Cr in Mar'25. Profit before tax saw a significant decline from 118.82 Cr in Mar'21 to 46.01 Cr in Mar'25, with profit after tax also decreasing from 83.11 Cr in Mar'21 to 42.93 Cr in Mar'25. The company's total assets increased from 342.95 Cr in Mar'20 to 814.15 Cr in Mar'25, while total liabilities rose from 182.57 Cr in Mar'21 to 272.27 Cr in Mar'25. Cash flow from operating activities showed a decline from 43.00 Cr in Mar'21 to 21.00 Cr in Mar'25, with net cash inflow remaining stable at 0.00 Cr in Mar'25. Overall, Bajaj Healthcare's financial performance reflects a mix of growth and challenges over the years.

Is Bajaj Healthcare overvalued or undervalued?

As of November 7, 2025, Bajaj Healthcare is considered overvalued with a PE ratio of 27.28, significantly higher than its peers like Cipla and Dr. Reddy's Labs, and has underperformed the Sensex with a year-to-date return of -24.7%.

As of 7 November 2025, Bajaj Healthcare's valuation grade has moved from fair to expensive, indicating a shift in its perceived market value. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 27.28, an EV to EBITDA of 18.91, and a PEG ratio of 0.83, which suggests that while the company is growing, its valuation may not be justified by its earnings growth prospects.<BR><BR>In comparison to its peers, Bajaj Healthcare's PE ratio is notably higher than Cipla's 22.33, which is rated attractive, and Dr. Reddy's Labs at 17.43, also attractive. This indicates that Bajaj Healthcare is trading at a premium relative to these competitors despite not offering a significantly better growth outlook. Additionally, the stock has underperformed against the Sensex in the year-to-date period, with a return of -24.7% compared to the Sensex's 6.50%, further reinforcing the notion that the stock may be overvalued in the current market environment.

Who are the top shareholders of the Bajaj Healthcare?

The top shareholders of Bajaj Healthcare include Sajankumar Rameshwarlal Bajaj with 37.59%, individual investors with 26.72%, and institutional investors, including mutual funds at 1.64% and foreign institutional investors at 1.05%. The largest public shareholder is Vanaja Sundar Iyer, holding 2.22% of the shares.

The top shareholders of Bajaj Healthcare include the promoters, with Sajankumar Rameshwarlal Bajaj holding the highest stake at 37.59%. Additionally, individual investors collectively own 26.72% of the shares. The company also has some institutional investment, with mutual funds holding 1.64% through one scheme and foreign institutional investors (FIIs) holding 1.05% across ten different entities. The highest public shareholder is Vanaja Sundar Iyer, who holds 2.22% of the shares.

When is the next results date for Bajaj Healthcare?

No Upcoming Board Meetings

What is the bonus history of the Bajaj Healthcare?

Bajaj Healthcare announced a 1:1 bonus issue on April 9, 2019, with a record date of April 10, 2019, granting shareholders one additional share for each share held.

Bajaj Healthcare has a bonus history that includes a 1:1 bonus issue announced on April 9, 2019. The record date for this bonus was April 10, 2019. This means that shareholders received one additional share for every share they held as of the record date.

Has Bajaj Healthcare declared dividend?

Yes, Bajaj Healthcare Ltd has declared a 20% dividend, amounting to ₹1 per share, with an ex-date of September 23, 2024. The company has shown strong total returns over various periods, including a 310.14% return over the last 5 years.

Bajaj Healthcare Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 1 per share<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.19%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Bajaj Healthcare experienced a price return of 21.85%, with no dividend return, resulting in a total return of 21.85%.<BR><BR>Over the past year, the company saw a price return of 81.69% and a dividend return of 0.32%, leading to a total return of 82.01%.<BR><BR>In a 2-year period, the price return was 76.99%, with a dividend return of 0.64%, culminating in a total return of 77.63%.<BR><BR>For the 3-year period, the price return stood at 67.82%, while the dividend return was 1.26%, resulting in a total return of 69.08%.<BR><BR>In the 4-year timeframe, the price return was 36.62%, with a dividend return of 1.04%, leading to a total return of 37.66%.<BR><BR>Over the last 5 years, Bajaj Healthcare achieved a remarkable price return of 307.08% and a dividend return of 3.06%, resulting in a total return of 310.14%.<BR><BR>Overall, Bajaj Healthcare's dividend declaration reflects a commitment to returning value to shareholders, and the substantial total returns across various periods indicate strong performance and growth potential for the company.